Argatroban Monohydrate cas: 141396-28-3 is a pharmaceutical drug that has been used to prevent blood clots in patients who are at risk of clotting. This drug belongs to the class of drugs known as anticoagulants, which work by interfering with the blood's ability to clot. Argatroban Monohydrate has been scientifically studied for its potential therapeutic uses and has been found to offer a range of health benefits.
Chemical Name:
The chemical name for Argatroban Monohydrate cas: 141396-28-3 is 1-[5-((aminoiminomethyl)amino]-1-oxo-2-[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]naphthalene-2-carboxylic acid, monohydrate.
Molecular Formula:
The molecular formula for Argatroban Monohydrate is C23H36N6O5S•H2O.
Formula Weight:
The formula weight for this drug is 528.65 g/mol.
CAS No:
Argatroban Monohydrate cas: 141396-28-3 is the CAS No (Chemical Abstracts Service Number) for this drug.
Top Ten Keywords and Synonyms:
Health Benefits of this Product:
Argatroban Monohydrate has been found to offer several health benefits. The primary use of this medication is to prevent blood clots in patients who are at risk of clotting. Some of the other potential health benefits of this drug include:
Prevention of thromboembolism: Argatroban Monohydrate is used primarily to prevent the formation of blood clots and, as a result, reduces the risk of thromboembolism, which can be life-threatening.
Reduction of the risk of stroke: Patients who are at risk of stroke due to atrial fibrillation or other conditions may benefit from treatment with Argatroban Monohydrate.
Hepatic impairment: Argatroban Monohydrate is sometimes used in patients with hepatic impairment as an alternative to heparin, which can be difficult to use in these patients.
Treatment of HIT: Argatroban Monohydrate is also used to treat heparin-induced thrombocytopenia (HIT), a condition in which an adverse reaction to heparin causes a reduction in blood platelets and the formation of blood clots.
Potential Effects:
Argatroban Monohydrate can have both beneficial and harmful effects. Some of the potential effects of this medication include:
Bleeding: Like other anticoagulants, Argatroban Monohydrate can increase the risk of bleeding, which can be serious or life-threatening.
Interactions with other medications: Argatroban Monohydrate can interact with other medications, including prescription and over-the-counter drugs, as well as herbal supplements.
Renal insufficiency: Argatroban Monohydrate can cause renal insufficiency in patients with pre-existing kidney disease.
Increased risk of thrombosis: In rare cases, Argatroban Monohydrate can increase the risk of thrombosis, particularly in patients with a history of thrombosis or in those with certain medical conditions.
Product Mechanism:
Argatroban Monohydrate is a synthetic thrombin inhibitor that works by blocking the enzyme thrombin, which plays a critical role in the formation of blood clots. By inhibiting thrombin, Argatroban Monohydrate can reduce the risk of thromboembolism and other serious medical conditions.
Safety:
Argatroban Monohydrate, like all medications, carries some risk of adverse effects. It is important for patients to discuss their medical history, current medications, and all other healthcare concerns with their healthcare provider before beginning treatment with Argatroban Monohydrate.
Side Effects:
Some of the most commonly reported side effects of Argatroban Monohydrate include bleeding, headache, fever, and nausea. Patients who experience any of these side effects or who develop other symptoms should contact their healthcare provider immediately.
Dosing Information:
Argatroban Monohydrate is typically administered intravenously and is dosed based on the patient's weight and the indication for treatment. Patients should receive regular monitoring of their blood clotting status to ensure that the medication is effective and that the patient is not experiencing any adverse effects.
Conclusion:
Argatroban Monohydrate is a medication that has been found to offer several health benefits, particularly in patients who are at risk of thromboembolism or who have hepatic impairment. As with all medications, it is important for patients to discuss their healthcare concerns with their healthcare provider and to follow all dosing instructions to ensure safe and effective treatment.
